RxDoctor Payments Data

Saman Lashkari, MD

Nephrology · Tarzana, CANPI 1447282421

Payments from drug & device makers

$11,606in general payments, 2019–2025

Across 604 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novo Nordisk$922
  • AstraZeneca$768
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$766
  • AbbVie$698
  • Johnson & Johnson$636
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,578100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)125$2,103
Novo Nordisk49$922
AstraZeneca(2 entities)37$768
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC52$766
AbbVie(2 entities)37$698
Johnson & Johnson37$636
Boehringer Ingelheim25$601
Novartis25$566
Otsuka America Pharmaceutical, Inc.26$558
Bayer20$430
Lilly USA, LLC19$377
Pfizer15$275
Eisai Inc.11$239
Merck9$217
GSK9$208
Sumitomo Pharma America, Inc.8$176
Takeda Pharmaceuticals U.S.A., Inc.7$137
Almatica Pharma LLC5$116
Astellas Pharma US Inc5$108
Lundbeck LLC4$107
Amarin Pharma, Inc.4$95
Biohaven Pharmaceutical Holding Company Ltd.4$77
Calliditas Therapeutics US Inc.3$73
E.r. Squibb & Sons, L.L.C.4$68
Idorsia Pharmaceuticals US Inc4$68
Mannkind Corporation4$68
Teva Pharmaceuticals USA, Inc.4$67
Lucid Diagnostics Inc.3$61
Bausch Health US, LLC3$60
Corcept Therapeutics2$58
Tolmar, Inc.3$55
Regeneron Healthcare Solutions, Inc.2$54
Dexcom, Inc.2$53
Alnylam Pharmaceuticals Inc.2$46
Abbott2$46
Exact Sciences3$45
Genentech USA, Inc.2$45
Tactile Systems Technology Inc3$42
Mallinckrodt Hospital Products Inc.1$33
Mallinckrodt Enterprises LLC1$32
Boston Scientific1$28
Mylan Specialty L.p.1$28
Linus Health, Inc.1$28
Zyla Life Sciences, Inc.2$26
Sanofi-aventis U.S. LLC1$25
Shield Therapeutics Inc1$24
Phathom Pharmaceuticals, Inc.1$24
Sanofi1$24
Xeris Pharmaceuticals, Inc.1$22
Radius Health, Inc.1$21
Philips North America LLC1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
Esperion Therapeutics, Inc.1$20
Optinose US, Inc.1$20
Paratek Pharmaceuticals, Inc.1$19
Seqirus USA Inc1$19
Vertiflex, Inc.1$17
Axsome Therapeutics, Inc.1$16
IBSA Pharma Inc.1$14
Nabriva Therapeutics, PLC1$14

How this compares

$11,606 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$598,508
Medicare patients
563
Services billed
6,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide316$318,739
MounjaroTirzepatide253$289,909
EliquisApixaban105$116,788
Repatha SureclickEvolocumab105$99,657
Praluent PenAlirocumab54$67,924
JardianceEmpagliflozin52$62,802
MyrbetriqMirabegron62$49,030
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate20$48,954
XareltoRivaroxaban49$45,489
KerendiaFinerenone28$39,031
FarxigaDapagliflozin Propanediol29$32,965
Wellbutrin XlBupropion Hcl12$30,085
JanumetSitagliptin Phos/Metformin Hcl36$29,198
TivicayDolutegravir Sodium12$25,744
LinzessLinaclotide27$24,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$922$335,205336 claims
Lilly USA, LLCMounjaro, Trulicity, Cymbalta$377$320,715281 claims
PfizerEliquis, Premarin, Paxlovid$275$133,639226 claims
Boehringer IngelheimJardiance, Synjardy Xr$601$74,71666 claims
Johnson & JohnsonXarelto, Procrit$636$58,03960 claims
AbbVieLinzess, Synthroid, Creon, Namzaric$698$53,723203 claims
Astellas Pharma US IncMyrbetriq$108$49,03062 claims
MerckJanumet, Januvia$217$47,15952 claims
BayerKerendia$430$39,03128 claims
AstraZenecaFarxiga$768$32,96529 claims
Sumitomo Pharma America, Inc.Gemtesa$176$15,17326 claims
GSKBreo Ellipta$208$8,76119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.

Other nephrology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →